{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["macular hole", "spectral domain optical coherence tomography", "symptomatic vitreomacular adhesion", "vitreomacular traction"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "34295149", "DateRevised": {"Year": "2022", "Month": "04", "Day": "25"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "07", "Day": "16"}], "ELocationID": ["10.2147/OPTH.S285464"], "Journal": {"ISSN": "1177-5467", "JournalIssue": {"Volume": "15", "PubDate": {"Year": "2021"}}, "Title": "Clinical ophthalmology (Auckland, N.Z.)", "ISOAbbreviation": "Clin Ophthalmol"}, "ArticleTitle": "Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study).", "Pagination": {"StartPage": "3109", "EndPage": "3120", "MedlinePgn": "3109-3120"}, "Abstract": {"AbstractText": ["To assess generalized (GD) and focal ellipsoid zone disruption (FD) in patients with symptomatic vitreomacular adhesion (sVMA) using spectral domain optical coherence tomography (SD-OCT) following ocriplasmin.", "OZONE was a Phase 4, retrospective study of patients with sVMA treated with a single intravitreal injection of ocriplasmin (0.125 mg). Data from adult patients with at least 6-month follow-up after ocriplasmin were included. SD-OCT was performed at baseline (within 30 days before ocriplasmin), before Day 21 post-injection (early observation, EO), and by last observation (LO) which was maximally 6 months post-injection. The main outcome measure was the development of new and the evolution of existing FD/GD at EO and LO.", "The study enrolled 134 eyes/patients from 22 sites in the USA. At baseline, 87 eyes (64.9%) had FD, 21 eyes (15.7%) had GD and 26 eyes (19.4%) had no FD/GD. Among the eyes without FD/GD at baseline, 13 (50%) and 8 (30.8%) developed FD or GD, respectively, by EO. By LO, FD/GD improvement or resolution was seen in >80% of these eyes. Among the eyes with FD/GD at baseline, <40% had improving/resolving EZ integrity at LO. The absence of FD/GD at baseline was associated with less persistent FD/GD at LO (P<0.0005). The presence of FD with MH at baseline was associated with persistent FD at LO (P=0.027).", "The fact that a large majority of eyes had FD/GD prior to ocriplasmin was unexpected and demonstrates that EZ disruptions are common in sVMA. This suggests that loss of EZ integrity may be part of the natural history of this disorder. It is hypothesized that the status of the EZ at baseline is a contributing, ocriplasmin independent modulator of subsequent EZ changes after ocriplasmin. Prospective analyses which include a sham control group would be required to test this hypothesis."], "CopyrightInformation": "\u00a9 2021 Drenser et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Associated Retinal Consultants P.C., Royal Oak, MI, USA."}], "LastName": "Drenser", "ForeName": "Kimberly A", "Initials": "KA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "California Retina Consultants, Santa Barbara, CA, USA."}, {"Identifier": [], "Affiliation": "California Retina Research Foundation, Santa Barbara, CA, USA."}], "LastName": "Pieramici", "ForeName": "Dante J", "Initials": "DJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Southeastern Retina Associates, Kingsport, TN, USA."}], "LastName": "Gunn", "ForeName": "Joseph M", "Initials": "JM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Weill-Cornell Medical College; MaculaCare, PLLC, New York, NY, USA."}], "LastName": "Rosberger", "ForeName": "Daniel F", "Initials": "DF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Oxurion NV (formerly ThromboGenics NV), Leuven, Belgium."}], "LastName": "Kozma", "ForeName": "Petra", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Mid Atlantic Retina, Philadelphia, PA, USA."}, {"Identifier": [], "Affiliation": "Wills Eye Hospital, Philadelphia, PA, USA."}], "LastName": "Fineman", "ForeName": "Mitchell S", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ghent University, Ghent, Belgium."}], "LastName": "Duchateau", "ForeName": "Luc", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sierra Eye Associates, Reno, NV, USA."}], "LastName": "Khanani", "ForeName": "Arshad M", "Initials": "AM"}], "PublicationTypeList": ["Case Reports", "Clinical Trial"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Clin Ophthalmol", "NlmUniqueID": "101321512", "ISSNLinking": "1177-5467"}, "CoiStatement": "K. Drenser is a consultant for Allergan, Genentech, and Spark Therapeutics. She is on the DSMB for Spark Therapeutics. She is the owner of FocusROP LLC and Retinal Solutions LLC. D. Pieramici and M. Fineman previously served as consultants for ThromboGenics. L. Duchateau is a consultant for Oxurion. P. Kozma is an employee of Oxurion. A. Khanani is a consultant for Adverum, Alcon, Allegro, Allergan, EyePoint, Genentech, Inc., Kodiak, Novartis, Gemini, Graybug, Gyroscope, Opthea, Oxurion, PolyPhotonix, RecensMedical, Regenxbio. He receives research support from Adverum, Allergan, Gemini, Genentech, Inc., Gyroscope, Kodiak, Novartis, Opthea, Ophthotech, Oxurion, Regenxbio, Recens Medical. He is a speaker for Allergan and Novartis. J. Gunn and D. Rosberger report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Tao LW, Wu Z, Guymer RH, Luu CD. Ellipsoid zone on optical coherence tomography: a review. Clin Exp Ophthalmol. 2016;44(5):422\u2013430. doi:10.1111/ceo.12685", "ArticleIdList": ["10.1111/ceo.12685", "26590363"]}, {"Citation": "Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina. 2011;31(8):1609\u20131619. doi:10.1097/IAE.0b013e3182247535", "ArticleIdList": ["10.1097/IAE.0b013e3182247535", "PMC3619110", "21844839"]}, {"Citation": "Zhu W, Chen H, Zhao H, et al. Automatic three-dimensional detection of photoreceptor ellipsoid zone disruption caused by trauma in the OCT. Sci Rep. 2016;6:25433. doi:10.1038/srep25433", "ArticleIdList": ["10.1038/srep25433", "PMC4860566", "27157473"]}, {"Citation": "Garc\u00eda-Layana A, Garc\u00eda-Arum\u00ed J, Ruiz-Moreno JM, Arias-Barquet L, Cabrera-L\u00f3pez F, Figueroa MS. A review of current management of vitreomacular traction and macular hole. J Ophthalmol. 2015;2015:809640. doi:10.1155/2015/809640", "ArticleIdList": ["10.1155/2015/809640", "PMC4363823", "25821592"]}, {"Citation": "Saxena S, Srivastav K, Cheung CM, Ng JYW, Lai TYY. Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography. Clin Ophthalmol. 2014;8:2507\u20132522. doi:10.2147/OPTH.S72132", "ArticleIdList": ["10.2147/OPTH.S72132", "PMC4266419", "25525329"]}, {"Citation": "Maheshwary AS, Oster SF, Yuson RMS, Cheng L, Mojana F, Freeman WR. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol. 2010;150(1):63\u201367 e1. doi:10.1016/j.ajo.2010.01.039", "ArticleIdList": ["10.1016/j.ajo.2010.01.039", "PMC2900476", "20451897"]}, {"Citation": "Oster SF, Mojana F, Brar M, Yuson RMS, Cheng L, Freeman WR. Disruption of the photoreceptor inner segment/outer segment layer on spectral domain-optical coherence tomography is a predictor of poor visual acuity in patients with epiretinal membranes. Retina. 2010;30(5):713\u2013718. doi:10.1097/IAE.0b013e3181c596e3", "ArticleIdList": ["10.1097/IAE.0b013e3181c596e3", "20038861"]}, {"Citation": "Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7):606\u2013615. doi:10.1056/NEJMoa1110823", "ArticleIdList": ["10.1056/NEJMoa1110823", "22894573"]}, {"Citation": "Nudleman E, Franklin MS, Wolfe JD, Williams GA, Ruby AJ. Resolution of subretinal fluid and outer retinal changes in patients treated with ocriplasmin. Retina. 2016;36(4):738\u2013743. doi:10.1097/IAE.0000000000000755", "ArticleIdList": ["10.1097/IAE.0000000000000755", "26398688"]}, {"Citation": "Singh RP, Li A, Bedi R, et al. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol. 2014;98(3):356\u2013360. doi:10.1136/bjophthalmol-2013-304219", "ArticleIdList": ["10.1136/bjophthalmol-2013-304219", "24357495"]}, {"Citation": "Tibbetts MD, Reichel E, Witkin AJ. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol. 2014;132(4):487\u2013490. doi:10.1001/jamaophthalmol.2013.8258", "ArticleIdList": ["10.1001/jamaophthalmol.2013.8258", "24577286"]}, {"Citation": "Itoh Y, Ehlers JP. Ellipsoid zone mapping and outer retinal characterization after intravitreal ocriplasmin. Retina. 2016;36(12):2290\u20132296. doi:10.1097/IAE.0000000000001110", "ArticleIdList": ["10.1097/IAE.0000000000001110", "PMC5115947", "27341665"]}, {"Citation": "Freund KB, Shah SA, Shah VP. Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye (Lond). 2013;27(6):773\u2013774. doi:10.1038/eye.2013.94", "ArticleIdList": ["10.1038/eye.2013.94", "PMC3682374", "23640609"]}, {"Citation": "Khanani AM, Duker JS, Heier JS, et al. Ocriplasmin treatment leads to symptomatic vitreomacular adhesion/vitreomacular traction resolution in the real-world setting: the Phase IV ORBIT study. Ophthalmol Retina. 2019;3(1):32\u201341. doi:10.1016/j.oret.2018.07.011", "ArticleIdList": ["10.1016/j.oret.2018.07.011", "30935657"]}, {"Citation": "Sharma P, Juhn A, Houston SK, et al. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol. 2015;159(5):861\u2013867. doi:10.1016/j.ajo.2015.01.034", "ArticleIdList": ["10.1016/j.ajo.2015.01.034", "25660387"]}, {"Citation": "Lavine JA, Srivastava SK, Dukkles N, Reese JL, Ehlers JP. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial. Br J Ophthalmol. 2020;104(3):410\u2013415. doi:10.1136/bjophthalmol-2019-314142", "ArticleIdList": ["10.1136/bjophthalmol-2019-314142", "31248879"]}, {"Citation": "Duker JS, Kaiser PK, Binder S, et al. The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120(12):2611\u20132619. doi:10.1016/j.ophtha.2013.07.042", "ArticleIdList": ["10.1016/j.ophtha.2013.07.042", "24053995"]}, {"Citation": "Fukumoto M, Sato T, Oosuka S, Kida T, Oku H, Ikeda T. Clinical features of vitreomacular traction syndrome with peripheral vitreoretinal adhesion. Clin Ophthalmol. 2020;14:281\u2013286. doi:10.2147/OPTH.S235670", "ArticleIdList": ["10.2147/OPTH.S235670", "PMC6995299", "32095069"]}, {"Citation": "Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2-year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) randomized trial. Ophthalmology. 2016;123(10):2232\u20132247. doi:10.1016/j.ophtha.2016.06.043", "ArticleIdList": ["10.1016/j.ophtha.2016.06.043", "27499517"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "11", "Day": "3"}, {"Year": "2021", "Month": "6", "Day": "28"}, {"Year": "2021", "Month": "7", "Day": "23", "Hour": "6", "Minute": "44"}, {"Year": "2021", "Month": "7", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "24", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "7", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["34295149", "PMC8291832", "10.2147/OPTH.S285464", "285464"]}}], "PubmedBookArticle": []}